Per Hydbring

Publications
Grants
CV
Public outreach and news

Articles

Article: JTO CLINICAL AND RESEARCH REPORTS. 2026;7(6):101003
Risk Factors for Developing Venous Thromboembolism in Patients With Advanced ALK-Rearranged NSCLC
Kamali C; Tsakonas G; Lewensohn R; Kanter L; Vikman H; Berglund A; Nedbaylo E; Hydbring P; Viktorsson K; De Petris L; Ekman S
Journal article: ESMO OPEN. 2026;11:106517
210eP Real-world treatment outcomes in ERBB2 exon 20-insertion mutated non-small cell lung cancer: A single-center Swedish cohort
Elyas KK; Ekman S; Hydbring P; de Petris L
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2026;15(1):e70219
Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance
Caceres-Verschae A; Haag P; Joelsson S; Hydbring P; Franzen B; Vegvari A; Eide IJZ; Agarwal N; Sahu SS; Stridfeldt F; De Petris L; Dev A; Ekman S; Brustugun OT; Lewensohn R; Viktorsson K
Article: ESMO OPEN. 2026;11(1):106028
Irradiated tumor volume as a predictor of local recurrence and radionecrosis in lung cancer with brain metastases treated with stereotactic radiosurgery
Koulouris A; Grundberg O; Skribek M; Kamali C; Hydbring P; Gubanski M; Ekman S; Tsakonas G
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2025;20(10):s806
EP.12.26 Multi-Omics Decipher the Molecular Landscape of EGFR+ Non-Small Cell Lung Cancer Patients Following Osimertinib Treatment
Braune E-B; Langels E; Eide IJZ; Grundberg O; De Petris L; Brustugun OT; Ekman S; Hydbring P
Article: COMPUTERS IN BIOLOGY AND MEDICINE. 2025;196(Pt B):110790
The stereotactic radiosurgery-brain prognostic index (SRS-BPI): A novel prognostic index for SRS-eligible lung cancer patients with brain metastases.
Koulouris A; Skribek M; Kamali C; Grundberg O; Gubanski M; Kalaitzidis K; Lampa E; Hydbring P; Ekman S; Tsakonas G
Journal article: ANNALS OF ONCOLOGY. 2025;36:s489-s490
EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases
Koulouris AV; Petrov I; Skribek MC; Hydbring P; Gubanski M; Ekman S; Tsakonas G
Article: EMBO MOLECULAR MEDICINE. 2025;17(4):10-774
Chaperone-mediated autophagy regulates the metastatic state of mesenchymal tumors
Zhou X; Berenger E; Shi Y; Shirokova V; Kochetkova E; Becirovic T; Zhang B; Kaminskyy VO; Esmaeilian Y; Hosaka K; Lindskog C; Hydbring P; Ekman S; Cao Y; Genander M; Iwanicki M; Norberg E; Vakifahmetoglu-Norberg H
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2024;13(11):0
Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study
Kamali C; Tsakonas G; Hydbring P; Jatta K; Berglund A; Viktorsson K; Lewensohn R; De Petris L; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2024;13(11):3152-3174
Construction and validation of a prognostic model based on oxidative stress-related genes in non-small cell lung cancer (NSCLC): predicting patient outcomes and therapy responses
Sun D; Lu J; Zhao W; Chen X; Xiao C; Hua F; Hydbring P; Gabazza EC; Tartarone A; Zhao X; Yang W
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2024;19(10):s623
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients
Braune E-B; Eide IJZ; Grundberg O; De Petris L; Brustugun OT; Ekman S; Hydbring P
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s353
P2.10-04 Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Kamali C; De Petris L; Jatta K; Viktorsson K; Lewensohn R; Ekman S; Hydbring P
Article: LUNG CANCER. 2023;182:107292
Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2022;17(9):s156
P2.13-03 Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2022;17(9):s574
EP16.02-008 Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer
Tsakonas G; Tadigotla V; Chakrabortty S; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(8):1678-1691
Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort
Wang Q; Wang Y; Wang X; Nakamura Y; Hydbring P; Yamauchi Y; Zhao X; Cao M
Article: CANCERS. 2022;14(14):3430
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Kosibaty Z; Brustugun OT; Eide IJZ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Kazmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Show more

All other publications

Preprint: BIORXIV. 2025
SURFR: genome-free discovery of cancer-unique small RNAs from cohort sequencing data
Kalogeropoulos P; Danilov K; Ulloa MA; Talanti A; Fromm B; Ekman S; Hydbring P; Friedländer MR
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2025;20(10)
Multi-Omics Decipher the Molecular Landscape of EGFR plus Non-Small Cell Lung Cancer Patients Following Osimertinib Treatment
Braune E-B; Langels E; Eide IJZ; Grundberg O; De Petris L; Brustugun OT; Ekman S; Hydbring P
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2024;19(10):S623
Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients
Braune E-B; Eide IJZ; Grundberg O; De Petris L; Brustugun OT; Ekman S; Hydbring P
Editorial: TRANSLATIONAL LUNG CANCER RESEARCH. 2024;13(9):0
Circulating tumor DNA (ctDNA)-the next generation biomarker in non-small cell lung cancer patients treated with immunotherapy?
Hydbring P
Meeting abstract: ANNALS OF ONCOLOGY. 2024;35:s858
The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Koulouris AV; Skribek MC; Kamali C; Grundberg O; Lampa E; Gubanski M; Hydbring P; Ekman S; Tsakonas G
Editorial: FRONTIERS IN IMMUNOLOGY. 2024;15:1407748
Immune-mediated damage to the heart and lungs in autoimmune diseases
Wei L; Hydbring P; Long L
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s647
EP12.01-18 Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; Zerdes I; Koulouris A; Hydbring P; Christopoulos P
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):S647
Validation of the ALK-Brain Prognostic Index (ALKBPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; Zerdes I; Koulouris A; Hydbring P; Christopoulos P
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):S353
Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Kamali C; De Petris L; Jatta K; Viktorsson K; Lewensohn R; Ekman S; Hydbring P
Editorial: TRANSLATIONAL LUNG CANCER RESEARCH. 2023;12(7):1358-1360
Targeting gene fusions in non-small cell lung cancer-a ceaseless success story?
Hydbring P
Editorial: TRANSLATIONAL LUNG CANCER RESEARCH. 2023;12(3):405-407
Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients
Hydbring P
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2022;17(9):S156
Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2022;17(9):S574
Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer
Tsakonas G; Tadigotla V; Chakrabortty S; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Editorial: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(9):1739-1741
Complex glandular pattern as an independent predictor of survival probability in lung adenocarcinoma
Hydbring P
Preprint: BIORXIV. 2022
Chaperone-mediated Autophagy Deficiency Reprograms Cancer Metabolism Via TGFβ Signaling to drive Mesenchymal Tumor Growth
Zhou X; Shi Y; Shirokova V; Kochetkova E; Becirovic T; Zhang B; Kaminskyy VO; Lindskog C; Hydbring P; Ekman S; Genander M; Norberg E; Vakifahmetoglu-Norberg H
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S654
Gene Expression Profiling of CNS Metastases in Non-Small Cell Lung Cancer - Matched Analyses with Primary Tumors
Tsakonas G; Hydbring P; Ekman S
Book chapter: THERANOSTIC BIONANOMATERIALS. 2019;p. 55-73
3 Nanoparticle Interaction With Immune Cells for Nanoparticle-Mediated (Anticancer) Immunotherapy
Hydbring P; Du J
Conference publication: EUROPEAN JOURNAL OF CANCER. 2018;103:E97
Extracellular vesicle analysis as non-invasive tool to predict and follow treatment response in bladder cancer
Haag P; Sha CH; Farnebo J; Hydbring P; Arapi V; Lewensohn R; Viktorsson K; Ullen A
Meeting abstract: CANCER RESEARCH. 2018;78(13):3952
Selective high affinity MYC- binding compound inhibits MYC-MAX interaction and MYC-dependent tumor cell growth
Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zinzalla G; Larsson L-G
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):S1921-S1922
Exosomal RNA-Profiling of Lung Pleural Effusions Identifies Adenocarcinoma Patients through Elevated miR-200 Expression
Hydbring P; De Petris L; Branden E; Koyi H; Novak M; Kanter L; Haag P; Hurley J; Tadigotla V; Skog J; Viktorsson K; Ekman S; Lewensohn R
Show more

Grants

Reactivating the pRb-pathway by targeting oncogenic microRNAs in treatment-refractory lung adenocarcinoma
Swedish Research Council
1 January 2020 - 31 December 2022

Employments

Lecturer, Department of Oncology-Pathology, Karolinska Institutet, 2024-
Senior Research Specialist, Department of Oncology-Pathology, Karolinska Institutet, 2022-

Degrees and Education

Docent, Karolinska Institutet, 2023

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI